Tìm theo
Ketoconazole
Các tên gọi khác (9 ) :
  • Extina
  • Ketoconazol
  • Ketoconazole
  • Ketoconazolum
  • Ketozole
  • Nizoral
  • Nizoral a-D
  • SID456469
  • Xolegel
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 65277-42-1
ATC: D01AC08, G01AF11, J02AB02
ĐG : Advanced Pharmaceutical Services Inc.
CTHH: C26H28Cl2N4O4
PTK: 531.431
Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C26H28Cl2N4O4
Phân tử khối
531.431
Monoisotopic mass
530.148760818
InChI
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3
InChI Key
InChIKey=XMAYWYJOQHXEEK-UHFFFAOYSA-N
IUPAC Name
1-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one
Traditional IUPAC Name
ketoconazole
SMILES
CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Độ tan chảy
146
Độ hòa tan
0.0866 mg/L
logP
4.35
logS
-4.8
pKa (Strongest Basic)
6.75
PSA
69.06 Å2
Refractivity
138.07 m3·mol-1
Polarizability
54.83 Å3
Rotatable Bond Count
7
H Bond Acceptor Count
6
H Bond Donor Count
0
Physiological Charge
0
Number of Rings
5
Bioavailability
1
MDDR-Like Rule
true
Dược Lực Học : Ketoconazole, like clotrimazole, fluconazole, itraconazole, and miconazole, is an imidazole antifungal agent.
Cơ Chế Tác Dụng : Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [PubChem] Ketoconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone.
Dược Động Học :
▧ Absorption :
Moderate
▧ Protein binding :
99% (in vitro, plasma protein binding)
▧ Metabolism :
Hepatic
▧ Half Life :
2 hours
Độc Tính : Hepatotoxicity, LD50=86 mg/kg (orally in rat)
Chỉ Định : For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
Tương Tác Thuốc :
  • Abiraterone Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
  • Acenocoumarol Ketoconazole may increase the anticoagulant effect of acenocoumarol.
  • Alfentanil Ketoconazole may increase the effect and toxicity of alfentanil.
  • Alfuzosin The antifungal increases the effect of alfuzosin
  • Aliskiren Monitor therapy due to increased serum concentration of aliskiren.
  • Almotriptan This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
  • Alprazolam Ketoconazole may increase the effect of the benzodiazepine, alprazolam.
  • Aluminium Aluminum-containing antacids may decrease the effect of ketoconazole.
  • Amitriptyline Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed.
  • Anisindione Ketoconazole may increase the anticoagulant effect of anisindione.
  • Apixaban Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration.
  • Aprepitant This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
  • Aripiprazole Ketoconazole may increase the effect of aripiprazole.
  • Artemether Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects.
  • Astemizole Increased risk of cardiotoxicity and arrhythmias
  • Atorvastatin Increased risk of myopathy/rhabdomyolysis
  • Avanafil Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax.
  • Bedaquiline Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely.
  • Bosentan Ketoconazole may increase the effect and toxicity of bosentan.
  • Bosutinib Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely.
  • Bromazepam Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed.
  • Budesonide Ketoconazole may increase levels/effect of budesonide.
  • Cabazitaxel Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
  • Calcium Calcium-containing antacids may decrease the absorption of ketoconazole.
  • Carbamazepine Ketoconazole may increase the effect of carbamazepine.
  • Cerivastatin Increased risk of myopathy/rhabdomyolysis
  • Chlordiazepoxide Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
  • Ciclesonide Increased effects/toxicity of ciclesonide
  • Cilostazol Ketoconazole may increase the effect of cilostazol.
  • Cimetidine The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole.
  • Cinacalcet Ketoconazole may increase the effect and toxicity of cinacalcet.
  • Cisapride Increased risk of cardiotoxicity and arrhythmias
  • Clobazam Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary.
  • Clonazepam Ketoconazole may increase the effect of the benzodiazepine, clonazepam.
  • Clorazepate Ketoconazole may increase the effect of the benzodiazepine, clorazepate.
  • Conivaptan Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
  • Crizotinib Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
  • Cyclosporine Ketoconazole may increase the effect of cyclosporine.
  • Dabigatran etexilate Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects.
  • Dabrafenib Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
  • Dantrolene Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed.
  • Darifenacin This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
  • Diazepam Ketoconazole may increase the effect of the benzodiazepine, diazepam.
  • Dicoumarol Ketoconazole may increase the anticoagulant effect of dicumarol.
  • Dihydroergotamine Possible ergotism and severe ischemia with this combination
  • Docetaxel Ketoconazole may increase the serum levels and toxicity of docetaxel.
  • Dofetilide This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
  • Dronedarone Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
  • Eletriptan This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
  • Eplerenone Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone.
  • Ergotamine Possible ergotism and severe ischemia with this combination.
  • Erlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinib
  • Esomeprazole The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole.
  • Estazolam Ketoconazole may increase the effect of the benzodiazepine, estazolam.
  • Ethinyl Estradiol This anti-infectious agent could decrease the effect of the oral contraceptive
  • Etravirine Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration. Ketoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for toxicity.
  • Everolimus Ketoconazole may increase everolimus levels/toxicity.
  • Famotidine The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.
  • Fentanyl Ketoconazole may increase levels/toxicity of fentanyl.
  • Fesoterodine Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine.
  • Fingolimod Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.
  • Flurazepam Ketoconazole may increase the effect of the benzodiazepine, flurazepam.
  • Fluticasone furoate Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely.
  • Galantamine Ketoconazole increases the effect and toxicity of galantamine
  • Gefitinib This CYP3A4 inhibitor increases levels/toxicity of gefitinib
  • Glimepiride Ketoconazole increases the effect of rosiglitazone
  • Halazepam Ketoconazole may increase the effect of the benzodiazepine, halazepam.
  • Haloperidol Ketoconazole may increase the effect and toxicity of haloperidol.
  • Iloperidone Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50%
  • Imatinib Ketoconazole may increase the levels of imatinib.
  • Imipramine Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed.
  • Indacaterol Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy.
  • Indinavir Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
  • Irinotecan Ketoconazole increases the effect and toxicity of irinotecan
  • Isoniazid Isoniazid decreases the effect of ketoconazole
  • Ivacaftor Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
  • Lansoprazole The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.
  • Levomilnacipran Strong CYP3A4 inhibitors may increase exposure levomilnacipran.
  • Lovastatin Increased risk of myopathy/rhabdomyolysis
  • Lurasidone Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
  • Magnesium oxide The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
  • Mestranol This anti-infectious agent could decrease the effect of the oral contraceptive
  • Methylprednisolone The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
  • Midazolam Ketoconazole may increase the effect of the benzodiazepine, midazolam.
  • Mirabegron Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely.
  • Nevirapine Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed.
  • Nizatidine The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.
  • Nortriptyline Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed.
  • Omeprazole The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.
  • Ospemifene Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions.
  • Pantoprazole The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole.
  • Pazopanib Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects.
  • Pimozide Increased risk of cardiotoxicity and arrhythmias
  • Pioglitazone Ketoconazole increases the effect of pioglitazone
  • Pomalidomide Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided.
  • Ponatinib Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
  • Prasugrel Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation.
  • Prednisolone The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
  • Prednisone The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
  • Quazepam Ketoconazole may increase the effect of the benzodiazepine, quazepam.
  • Quetiapine Ketoconazole may increase the therapeutic and adverse effects of quetiapine.
  • Quinidine Ketoconazole may increase the effect and toxicity of quinidine.
  • Quinidine barbiturate Ketoconazole may increase the effect and toxicity of quinidine barbiturate.
  • Rabeprazole The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.
  • Ramelteon Ketoconazole may increase the serum levels and toxicity of ramelteon.
  • Ranitidine The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole.
  • Ranolazine Increased levels of ranolazine - risk of toxicity
  • Regorafenib Strong CYP3A4 inhibitors may increase levels of regorafenib.
  • Rifampicin Rifampin may decrease the effect of ketoconazole.
  • Ritonavir Ketoconazole may increase the effect and toxicity of ritonavir.
  • Rivaroxaban Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
  • Roflumilast Increases roflumilast levels.
  • Rosiglitazone Ketoconazole increases the effect of rosiglitazone
  • Ruxolitinib Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
  • Saquinavir Ketoconazole may increase the effect and toxicity of saquinavir.
  • Saxagliptin Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day.
  • Sibutramine Ketoconazole increases the levels and toxicity of sibutramine
  • Sildenafil Ketoconazole may increase the effect and toxicity of sildenafil.
  • Silodosin Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects
  • Simvastatin Increased risk of myopathy/rhabdomyolysis
  • Sirolimus Ketoconazole may increase the effect and toxicity of sirolimus.
  • Solifenacin This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
  • Sucralfate Sucralfate may decrease the absorption of ketoconazole.
  • Sunitinib Possible increase in sunitinib levels
  • Tacrine The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed.
  • Tacrolimus The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered.
  • Tadalafil Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
  • Tamoxifen Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed.
  • Tamsulosin Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed.
  • Telaprevir Strong CYP3A4 inhibitors increase exposure of telaprevir.
  • Telithromycin Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
  • Temsirolimus Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
  • Teniposide The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed.
  • Terfenadine Increased risk of cardiotoxicity and arrhythmias
  • Thiothixene The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
  • Tiagabine The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed.
  • Tipranavir Tipranavir may increase the serum concentration of Ketoconazole.
  • Tizanidine Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
  • Tolbutamide Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
  • Tolterodine Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
  • Tolvaptan Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%.
  • Topotecan The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
  • Torasemide Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed.
  • Tramadol Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production.
  • Trazodone The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed.
  • Triazolam Ketoconazole may increase the effect of the benzodiazepine, triazolam.
  • Trimethoprim The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed.
  • Trimipramine The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed.
  • Ulipristal Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy.
  • Valdecoxib Ketoconazole may increase the effect and toxicity of valdecoxib.
  • Vardenafil Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
  • Vemurafenib Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
  • Venlafaxine Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.
  • Verapamil Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed.
  • Vilazodone CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
  • Vinblastine Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed.
  • Vincristine Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed.
  • Vinorelbine Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed.
  • Voriconazole Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.
  • Warfarin Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.
  • Zafirlukast Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed.
  • Ziprasidone Ketoconazole increases the effect and toxicity of ziprasidone
  • Zolpidem Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed.
  • Zonisamide Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed.
  • Zopiclone Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Cream - Topical
Shampoo - Topical
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Stiefel
    Sản phẩm biệt dược : Extina
  • Công ty : Janssen-Cilag
    Sản phẩm biệt dược : Fungarest
  • Sản phẩm biệt dược : Fungoral
  • Công ty :
    Sản phẩm biệt dược : Ketodan
  • Công ty : Hessel
    Sản phẩm biệt dược : Ketoderm
  • Công ty : Isdin
    Sản phẩm biệt dược : Ketoisdin
  • Công ty : Ranbaxy
    Sản phẩm biệt dược : Ketozole
  • Công ty : Ortho-McNeil
    Sản phẩm biệt dược : Nizoral
  • Công ty : Ortho-McNeil
    Sản phẩm biệt dược : Nizoral Cream
  • Công ty : Ortho-McNeil
    Sản phẩm biệt dược : Nizoral Shampoo
  • Công ty : Janssen
    Sản phẩm biệt dược : Orifungal
  • Công ty : Janssen
    Sản phẩm biệt dược : Orifungal M
  • Công ty : Esteve
    Sản phẩm biệt dược : Panfungol
  • Công ty :
    Sản phẩm biệt dược : Xolegel
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01026
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00351
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31768
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0145-0003-05
PharmGKB
http://www.pharmgkb.org/drug/PA450146
Wikipedia
http://en.wikipedia.org/wiki/Ketoconazole
RxList
http://www.rxlist.com/cgi/generic/ketocon.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/niz1297.shtml
Drugs.com
http://www.drugs.com/cdi/ketoconazole.html
... loading
... loading